An Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of NNC0165-1562 and Semaglutide in Subjects With Overweight or Obesity
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Peptide-YY-Novo-Nordisk (Primary) ; Semaglutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 14 Aug 2019 Status changed from active, no longer recruiting to completed.
- 11 Jun 2019 Planned number of patients changed from 36 to 37.
- 11 Jun 2019 Planned End Date changed from 22 Aug 2019 to 29 Jul 2019.